Future oncology
A high-frequency clinical oncology journal formerly from Future Medicine and now published by Taylor & Francis. It carries trial protocols, reviews and original research and is read by clinical oncologists and industry researchers.
Overview
Future Oncology is published by Taylor & Francis (Informa UK). The NLM Catalog records that it began in 2005 in London with Future Medicine Ltd, moved to Taylor & Francis in 2024, increased from thirty-six issues a year (2019 to 2021) to forty issues a year from 2022, and is indexed in MEDLINE with content deposited in PubMed Central. Crossref lists Informa UK (Taylor & Francis) as publisher.
GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.
Sara López-Tarruella is a breast oncologist leading GEICAM neoadjuvant studies in triple-negative disease.